Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion its initial public offering in the United States.
Use the vitals package with ellmer to evaluate and compare the accuracy of LLMs, including writing evals to test local models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results